Moderna & Pfizer commence late-stage COVID-19 vaccine trials in U.S.
Category: #health  By Saipriya Iyer  Date: 2020-07-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna & Pfizer commence late-stage COVID-19 vaccine trials in U.S.

Moderna, a biotechnology company, and NIH (National Institute of Health) have reportedly collaborated to start the Phase 3 clinical trial of a potential COVID-19 vaccine.

The trial will examine the safety and efficacy of the vaccine in the U.S. It will enroll 30,000 subjects at over 89 sites across the country. Half the participants will receive 2 shots of their vaccine 28 days apart, while the other half will receive 2 shots of the saltwater placebo. Researchers will then monitor the occurrence of any adverse events as well as the effectiveness of the vaccine to determine whether it can prevent the COVID-19 disease.

Dr. Anthony S. Fauci, director of NIH, has estimated that the results or data from the Moderna trial are expected to be available by November 2020. He has further stated that 150-160 COVID-19 infections will be enough for determining the effectiveness of the vaccine.

Apart from Moderna, Pfizer also has recently announced the commencement of a late-stage COVID-19 vaccine trial, in collaboration with BioNTech. For this study, the company will enroll 30,000 participants from 39 U.S. states as well as from Germany, Argentina, and Brazil.

The U.S. government previously announced that it had signed a $1.95 billion agreement with Pfizer to buy 100 million doses of its vaccine by 2020 end if the trial proves the safety and efficacy of the vaccine. Both Pfizer/BioNTech and Moderna vaccines adopt a synthetic version of the genetic material from the virus, also known as mRNA (messenger RNA).

Earlier trials of the vaccine by Moderna revealed the stimulation of a strong immune response by the subjects, with transient and minor side effects including fatigue, fever, achiness, and sore arms. The biotech company has cited that it would deliver nearly 500 million vaccine doses per year and increase it up to a billion per year from 2021. It also obtained a $1 billion funding from the federal government for vaccine development.

Source credit:

https://www.nytimes.com/2020/07/27/health/moderna-vaccine-covid.html



About Author

Saipriya Iyer

Email: [email protected]ters.com   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Montero inks agreement to acquire Isabella Gold Silver Project
Montero inks agreement to acquire Isabella Gold Silver Project
By Saipriya Iyer

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration cla...

PharmaCyte to submit IND application to FDA for clinical trial in LAPC
PharmaCyte to submit IND application to FDA for clinical trial in LAPC
By Saipriya Iyer

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among...

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial
By Saipriya Iyer

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available s...